178 related articles for article (PubMed ID: 25601988)
1. Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenase.
Tiernan CT; Edwin EA; Hawong HY; Ríos-Cabanillas M; Goudreau JL; Atchison WD; Lookingland KJ
Toxicol Sci; 2015 Apr; 144(2):347-56. PubMed ID: 25601988
[TBL] [Abstract][Full Text] [Related]
2. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
[TBL] [Abstract][Full Text] [Related]
3. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Lamensdorf I; Eisenhofer G; Harvey-White J; Nechustan A; Kirk K; Kopin IJ
Brain Res; 2000 Jun; 868(2):191-201. PubMed ID: 10854571
[TBL] [Abstract][Full Text] [Related]
4. The role of de novo catecholamine synthesis in mediating methylmercury-induced vesicular dopamine release from rat pheochromocytoma (PC12) cells.
Tiernan CT; Edwin EA; Goudreau JL; Atchison WD; Lookingland KJ
Toxicol Sci; 2013 May; 133(1):125-32. PubMed ID: 23425605
[TBL] [Abstract][Full Text] [Related]
5. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.
Jinsmaa Y; Florang VR; Rees JN; Anderson DG; Strack S; Doorn JA
Chem Res Toxicol; 2009 May; 22(5):835-41. PubMed ID: 19388687
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal.
Florang VR; Rees JN; Brogden NK; Anderson DG; Hurley TD; Doorn JA
Neurotoxicology; 2007 Jan; 28(1):76-82. PubMed ID: 16956664
[TBL] [Abstract][Full Text] [Related]
7. Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons.
Doorn JA; Florang VR; Schamp JH; Vanle BC
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S73-5. PubMed ID: 24262193
[TBL] [Abstract][Full Text] [Related]
8. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde.
Lamensdorf I; Eisenhofer G; Harvey-White J; Hayakawa Y; Kirk K; Kopin IJ
J Neurosci Res; 2000 May; 60(4):552-8. PubMed ID: 10797558
[TBL] [Abstract][Full Text] [Related]
9. Reduced methylmercury accumulation in a methylmercury-resistant rat pheochromocytoma PC12 cell line.
Miura K; Clarkson TW
Toxicol Appl Pharmacol; 1993 Jan; 118(1):39-45. PubMed ID: 8430423
[TBL] [Abstract][Full Text] [Related]
10. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
[TBL] [Abstract][Full Text] [Related]
11. The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
Rooke N; Li DJ; Li J; Keung WM
J Med Chem; 2000 Nov; 43(22):4169-79. PubMed ID: 11063613
[TBL] [Abstract][Full Text] [Related]
12. Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Sharabi Y; Mash DC
Parkinsonism Relat Disord; 2015 Jun; 21(6):567-72. PubMed ID: 25829070
[TBL] [Abstract][Full Text] [Related]
13. Effects of methylmercury on dopamine release in MN9D neuronal cells.
Shao Y; Chan HM
Toxicol Mech Methods; 2015; 25(8):637-44. PubMed ID: 26056851
[TBL] [Abstract][Full Text] [Related]
14. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate.
Rees JN; Florang VR; Anderson DG; Doorn JA
Chem Res Toxicol; 2007 Oct; 20(10):1536-42. PubMed ID: 17887726
[TBL] [Abstract][Full Text] [Related]
15. Dihydroxyphenylacetaldehyde Lowering Treatment Improves Locomotor and Neurochemical Abnormalities in the Rat Rotenone Model: Relevance to the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson's Disease.
Khashab R; Gutman-Sharabi N; Shabtai Z; Landau R; Halperin R; Fay-Karmon T; Leibowitz A; Sharabi Y
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569897
[TBL] [Abstract][Full Text] [Related]
16. Neurotransmitter amines and antioxidant agents in neuronal protection against methylmercury-induced cytotoxicity in primary cultures of mice cortical neurons.
Olguín N; Müller ML; Rodríguez-Farré E; Suñol C
Neurotoxicology; 2018 Dec; 69():278-287. PubMed ID: 30075218
[TBL] [Abstract][Full Text] [Related]
17. Methylmercury inhibits dopaminergic function in rat pup synaptosomes in an age-dependent manner.
Dreiem A; Shan M; Okoniewski RJ; Sanchez-Morrissey S; Seegal RF
Neurotoxicol Teratol; 2009; 31(5):312-7. PubMed ID: 19464365
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of glutathione and cysteine on the methylmercury-induced striatal dopamine release in vivo.
Faro LR; do Nascimento JL; Campos F; Vidal L; Alfonso M; Durán R
Life Sci; 2005 Jun; 77(4):444-51. PubMed ID: 15894013
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of lycopene against methylmercury-induced neurotoxicity in cultured rat cerebellar granule neurons.
Qu M; Nan X; Gao Z; Guo B; Liu B; Chen Z
Brain Res; 2013 Dec; 1540():92-102. PubMed ID: 24120987
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of methylmercury-resistant PC12 cell line.
Miura K; Clarkson TW; Ikeda K; Naganuma A; Imura N
Environ Health Perspect; 1994 Sep; 102 Suppl 3(Suppl 3):313-5. PubMed ID: 7843125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
